DYN
Price
$13.18
Change
-$0.26 (-1.93%)
Updated
Sep 23, 04:59 PM (EDT)
Capitalization
1.88B
36 days until earnings call
RNA
Price
$42.30
Change
-$0.04 (-0.09%)
Updated
Sep 23, 04:59 PM (EDT)
Capitalization
6.18B
49 days until earnings call
Interact to see
Advertisement

DYN vs RNA

Header iconDYN vs RNA Comparison
Open Charts DYN vs RNABanner chart's image
Dyne Therapeutics
Price$13.18
Change-$0.26 (-1.93%)
Volume$27.79K
Capitalization1.88B
Avidity Biosciences
Price$42.30
Change-$0.04 (-0.09%)
Volume$36.08K
Capitalization6.18B
DYN vs RNA Comparison Chart in %
Loading...
DYN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DYN vs. RNA commentary
Sep 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DYN is a Hold and RNA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 24, 2025
Stock price -- (DYN: $13.44 vs. RNA: $42.34)
Brand notoriety: DYN and RNA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DYN: 91% vs. RNA: 59%
Market capitalization -- DYN: $1.88B vs. RNA: $6.18B
DYN [@Biotechnology] is valued at $1.88B. RNA’s [@Biotechnology] market capitalization is $6.18B. The market cap for tickers in the [@Biotechnology] industry ranges from $97.36B to $0. The average market capitalization across the [@Biotechnology] industry is $1.92B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DYN’s FA Score shows that 1 FA rating(s) are green whileRNA’s FA Score has 0 green FA rating(s).

  • DYN’s FA Score: 1 green, 4 red.
  • RNA’s FA Score: 0 green, 5 red.
According to our system of comparison, DYN is a better buy in the long-term than RNA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DYN’s TA Score shows that 4 TA indicator(s) are bullish while RNA’s TA Score has 5 bullish TA indicator(s).

  • DYN’s TA Score: 4 bullish, 3 bearish.
  • RNA’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, both DYN and RNA are a good buy in the short-term.

Price Growth

DYN (@Biotechnology) experienced а +4.51% price change this week, while RNA (@Biotechnology) price change was +5.27% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.94%. For the same industry, the average monthly price growth was +8.31%, and the average quarterly price growth was +48.45%.

Reported Earning Dates

DYN is expected to report earnings on Oct 30, 2025.

RNA is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+2.94% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RNA($6.18B) has a higher market cap than DYN($1.88B). RNA YTD gains are higher at: 45.598 vs. DYN (-42.954). DYN has higher annual earnings (EBITDA): -437.37M vs. RNA (-518.74M). RNA has more cash in the bank: 1.18B vs. DYN (684M). RNA has less debt than DYN: RNA (5.14M) vs DYN (121M). RNA has higher revenues than DYN: RNA (10.7M) vs DYN (0).
DYNRNADYN / RNA
Capitalization1.88B6.18B30%
EBITDA-437.37M-518.74M84%
Gain YTD-42.95445.598-94%
P/E RatioN/AN/A-
Revenue010.7M-
Total Cash684M1.18B58%
Total Debt121M5.14M2,356%
TECHNICAL ANALYSIS
Technical Analysis
DYNRNA
RSI
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
79%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
85%
Momentum
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
84%
MACD
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
87%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 6 days ago
85%
Bullish Trend 19 days ago
85%
Declines
ODDS (%)
Bearish Trend 9 days ago
88%
Bearish Trend 13 days ago
85%
BollingerBands
ODDS (%)
N/A
Bullish Trend 2 days ago
85%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
DYN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NFEPX22.880.10
+0.44%
Columbia Large Cap Growth Opp Inst
DRECX41.32N/A
N/A
Davis Real Estate C
FCVAX19.54N/A
N/A
Fidelity Advisor Small Cap Value A
RWMGX67.05-0.02
-0.03%
American Funds Washington Mutual R6
TGDVX17.52-0.02
-0.11%
TCW Relative Value Large Cap N

DYN and

Correlation & Price change

A.I.dvisor indicates that over the last year, DYN has been loosely correlated with XNCR. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if DYN jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DYN
1D Price
Change %
DYN100%
+2.36%
XNCR - DYN
58%
Loosely correlated
+0.97%
RNA - DYN
58%
Loosely correlated
+3.12%
CRNX - DYN
57%
Loosely correlated
-0.56%
SYRE - DYN
53%
Loosely correlated
+2.76%
IDYA - DYN
52%
Loosely correlated
+0.70%
More

RNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, RNA has been loosely correlated with DYN. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if RNA jumps, then DYN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RNA
1D Price
Change %
RNA100%
+3.12%
DYN - RNA
58%
Loosely correlated
+2.36%
OCUL - RNA
52%
Loosely correlated
+0.83%
ACLX - RNA
52%
Loosely correlated
+0.46%
CRNX - RNA
49%
Loosely correlated
-0.56%
NRIX - RNA
46%
Loosely correlated
-0.12%
More